Skip to main content

3 Result(s)

within Brent W. Sutherland Remove this filter Biomedicine Remove this filter English Remove this filter

and

  1. No Access

    Article

    Liposomal OTS964, a TOPK inhibitor: a simple method to estimate OTS964 association with liposomes that relies on enhanced OTS964 fluorescence when bound to albumin

    OTS964 is an inhibitor of T-lymphokine-activated killer cell-originated protein kinase (TOPK), a protein kinase important for mitosis and highly expressed in ovarian and lung cancers. This compound demonstrate...

    Roger Gilabert-Oriol, Brent W. Sutherland… in Drug Delivery and Translational Research (2019)

  2. Article

    Open Access

    The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion

    Over-expression of insulin-like growth factor 2 mRNA binding protein 3 (IMP3) is correlated with poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Previous studies examining other cancer types have im...

    Clarissa C Pasiliao, Che-Wei A Chang, Brent W Sutherland, Shannon M Valdez… in BMC Cancer (2015)

    Download PDF (970 KB) View Article

  3. Article

    Open Access

    QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

    Substantial preclinical evidence has indicated that inhibition of integrin linked-kinase (ILK) correlates with cytotoxic/cytostatic cellular effects, delayed tumor growth in animal models of cancer, and inhibi...

    Jessica Kalra, Corinna Warburton, Karen Fang, Lincoln Edwards… in Breast Cancer Research (2009)

    Download PDF (3379 KB) View Article